Two different risk models for identification of cancer patients at high risk of VTE
Khorana VTE risk assessment score5 . | Points . | ||
---|---|---|---|
Site of cancer | Very high risk | Stomach, pancreas | 2 |
High risk | Lung, lymphoma, gynecologic, bladder, testicular | 1 | |
Platelet count | ≥350 × 109/L | 1 | |
Hemoglobin and/or use of erythropoiesis-stimulating agents | <10 g/dL | 1 | |
Leukocyte count | >11 × 109/L | 1 | |
Body mass index | ≥35 kg/m2 | 1 | |
Vienna VTE risk assessment score,19 addition of | |||
d-dimer | ≥1.44 μg/mL | 1 | |
sP-selectin | ≥53.1 mg/mL | 1 |
Khorana VTE risk assessment score5 . | Points . | ||
---|---|---|---|
Site of cancer | Very high risk | Stomach, pancreas | 2 |
High risk | Lung, lymphoma, gynecologic, bladder, testicular | 1 | |
Platelet count | ≥350 × 109/L | 1 | |
Hemoglobin and/or use of erythropoiesis-stimulating agents | <10 g/dL | 1 | |
Leukocyte count | >11 × 109/L | 1 | |
Body mass index | ≥35 kg/m2 | 1 | |
Vienna VTE risk assessment score,19 addition of | |||
d-dimer | ≥1.44 μg/mL | 1 | |
sP-selectin | ≥53.1 mg/mL | 1 |
In the CATS, brain tumors (high-grade glioma) were allocated to the very high risk sites of cancer.